TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
TG Therapeutics announced that its Phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure between the approved two-infusion initiation regimen for BRIUMVI and a new single 600 mg infusion on Day 1 only, potentially streamlining treatment initiation for relapsing forms of multiple sclerosis (RMS). The simplified do…